Efficacy and safety of immunotherapy in cervical cancer: a review of advances in immune-related therapy for cervical cancer

Abstract

Abstract Purpose Immunotherapy is emerging as a promising approach for cervical cancer treatment, with new targets and drugs continuously being developed. In response to the wide range of immunotherapies currently available, this article aims to review and sort the immunotherapy for cervical cancer and the advancements in assessing effectiveness and prognosis. Results The result shows that immune checkpoint inhibitors are highly effective in various immunotherapies for cervical cancer. The most commonly used immunotherapies for advanced cervical cancer are programmed death-1 (PD-1) and programmed death ligand-1 (PD-L1) inhibitors. Other options include tumor cell vaccines and genetically engineered T-cells. It is important to note that immunotherapy in combination with other treatments has been shown to be more effective than using immunotherapy alone. Moreover, when considering treatment efficacy, it may be helpful to focus on biomarkers such as Circulating Tumor Cells (CTCs), microRNAs, Long Non-coding RNAs, Circular RNAs, Tumor Mutational Burden (TMB), and tumor infiltrating lymphocytes (TILs). Conclusion This review catches the latest progress in immunotherapy for cervical cancer and in assessing effectiveness and prognosis. Immunotherapy, particularly immune checkpoint inhibitors, is gaining ground in cervical cancer treatment. Relevant studies on biological indicators for the assessment of the efficacy of immunotherapy are also under way.

Keywords

• Cervical cancer
• Immunotherapy
• Antibody
• Vaccine
• Biomarker